CD73 & THROMBOMODULIN
CD73
基本信息
- 批准号:7960583
- 负责人:
- 金额:$ 6.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-15 至 2010-04-30
- 项目状态:已结题
- 来源:
- 关键词:AdenosineAgonistAutoimmunityBindingCoagulation ProcessComputer Retrieval of Information on Scientific Projects DatabaseEndothelial CellsFundingGeneticGlycosylphosphatidylinositolsGrantIn VitroInflammatoryInstitutionIntegral Membrane ProteinLinkMeasuresMembrane ProteinsMolecularMusPathway interactionsPlasmaProtein CProtein DephosphorylationPurinergic P1 ReceptorsRegulationResearchResearch PersonnelResourcesRoleSignal PathwaySourceSubstrate SpecificitySurfaceSystemThrombinThrombomodulinUnited States National Institutes of HealthWild Type Mouseextracellularin vivomouse model
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
CD73 is a glycosylphosphatidylinositol (GPI)-linked membrane protein that catalyzes the extracellular dephosphorylation of AMP to adenosine. Thrombomodulin (TM) is a type I transmembrane protein located on the surface of endothelial cells. It serves as a thrombin modulator, since thrombin's substrate specificity is switched once binding to TM. In this study, we proposed that CD73-generated adenosine regulates TM expression and TM is a target of the CD73-generated adenosine signaling pathway. The specific aims are: 1. To delineate the pathway of CD73 regulated TM expression and the impact on TM functions in cultured endothelial cells. 2. To study the role of CD73 on TM regulation and the impact on TM functions in mouse model. 3. To study the role of anti-coagulation system involved in CD73 functions.
Our preliminary results indicated that TM expression levels were up-regulated by an adenosine receptor agonist in vitro and in vivo. CD73-generated adenosine also can increase TM expression in vitro. In this proposal, we will identify the adenosine receptor subtype responsible for TM regulation and the downstream effectors. The impact on TM functions will be characterized by protein C activation on endothelial cells. We have compared TM expression levels in CD73-/- mice to that in wild type mice under normal conditions. These comparisons will be carried out under inflammatory conditions. The impact on TM functions will be characterized by measuring APC level in plasma in wild type mice and CD73-/- mice under inflammatory conditions. The impact of anti-coagulation system on CD73 functions will also be studied under several experimental settings.
这个子项目是许多利用
由NIH/NCRR资助的中心赠款提供的资源。子项目和
研究者(PI)可能从另一个NIH来源获得了主要资金,
因此可以在其他CRISP条目中表示。列出的机构为
研究中心,而研究中心不一定是研究者所在的机构。
CD 73是一种糖基磷脂酰肌醇(GPI)连接的膜蛋白,催化AMP的细胞外去磷酸化为腺苷。血栓调节蛋白(TM)是位于内皮细胞表面的I型跨膜蛋白。它作为凝血酶调节剂,因为凝血酶的底物特异性一旦与TM结合就被转换。在这项研究中,我们提出,CD 73产生的腺苷调节TM的表达和TM是一个目标的CD 73产生的腺苷信号通路。具体目标是:1.探讨CD 73调控内皮细胞TM表达的途径及其对TM功能的影响。2.目的研究CD 73在TM调节中的作用及对TM功能的影响。3.目的:探讨抗凝系统在CD 73功能中的作用。
我们的初步结果表明,TM表达水平上调腺苷受体激动剂在体外和体内。CD 73产生的腺苷也可以在体外增加TM表达。在这个提议中,我们将确定负责TM调节的腺苷受体亚型和下游效应子。对TM功能的影响将通过蛋白C对内皮细胞的激活来表征。我们比较了正常条件下CD 73-/-小鼠与野生型小鼠的TM表达水平。这些比较将在炎症条件下进行。通过测量炎症条件下野生型小鼠和CD 73-/-小鼠血浆中的APC水平来表征对TM功能的影响。还将在几个实验设置下研究抗凝系统对CD 73功能的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARTA E ALARCON-RIQUELME其他文献
MARTA E ALARCON-RIQUELME的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARTA E ALARCON-RIQUELME', 18)}}的其他基金
UNDERSTANDING THE EFFECTS OF THE HUMAN SLE-ASSOCIATED BANK1 MUTATIONS
了解人类 SLE 相关 Bank1 突变的影响
- 批准号:
8359791 - 财政年份:2011
- 资助金额:
$ 6.59万 - 项目类别:
UNDERSTANDING THE EFFECTS OF THE HUMAN SLE-ASSOCIATED BANK1 MUTATIONS
了解人类 SLE 相关 Bank1 突变的影响
- 批准号:
8168259 - 财政年份:2010
- 资助金额:
$ 6.59万 - 项目类别:
Identification of Susceptibility Genes for SLE of Amerindian Origin in Hispanics
西班牙裔美洲印第安人 SLE 易感基因的鉴定
- 批准号:
7834773 - 财政年份:2009
- 资助金额:
$ 6.59万 - 项目类别:
Fine Mapping and Replication of a Genome-Wide Association Scan for SLE in Hispani
西班牙裔 SLE 的全基因组关联扫描的精细绘图和复制
- 批准号:
7743712 - 财政年份:2009
- 资助金额:
$ 6.59万 - 项目类别:
Fine Mapping and Replication of a Genome-Wide Association Scan for SLE in Hispani
西班牙裔 SLE 的全基因组关联扫描的精细绘图和复制
- 批准号:
8112249 - 财政年份:2009
- 资助金额:
$ 6.59万 - 项目类别:
Identification Of Susceptibility Genes For SLE Of Amerindian Origin In Hispanics
西班牙裔美洲印第安人 SLE 易感基因的鉴定
- 批准号:
7774742 - 财政年份:2009
- 资助金额:
$ 6.59万 - 项目类别:
Identification of Susceptibility Genes for SLE of Amerindian Origin in Hispanics
西班牙裔美洲印第安人 SLE 易感基因的鉴定
- 批准号:
7943882 - 财政年份:2009
- 资助金额:
$ 6.59万 - 项目类别:
Identification Of Susceptibility Genes For SLE Of Amerindian Origin In Hispanics
西班牙裔美洲印第安人 SLE 易感基因的鉴定
- 批准号:
8514482 - 财政年份:
- 资助金额:
$ 6.59万 - 项目类别:
Identification Of Susceptibility Genes For SLE Of Amerindian Origin In Hispanics
西班牙裔美洲印第安人 SLE 易感基因的鉴定
- 批准号:
8380582 - 财政年份:
- 资助金额:
$ 6.59万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 6.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 6.59万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 6.59万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 6.59万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 6.59万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 6.59万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 6.59万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 6.59万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 6.59万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 6.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)